The U.S. market for remote monitoring reached $10.8 billion last year. Healthcare facilities see it as a way to track patient vital signs to spot potential problems earlier and avoid unnecessary healthcare costs, particularly after patients with chronic conditions are discharged. A Pittsburgh company has taken a novel approach to this need by developing a noninvasive FDA approved device that can measure oxygen saturation of arterial hemoglobin and pulse rate in adult and pediatric patients in realtime.
It can also calculate the percentage of change in pulse rate and pulse strength derived from data recorded with a pulse oximeter to track any deterioration in cardiac stability.
President and CEO Frank Amoruso told MedCity News that the device would initially be used in situations where healthcare professionals need to monitor patients for any change in cardiovascular stability. Its initial applications would be for hemodialysis, long-term care and nursing homes.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Intelomed has raised $4 million to support the product launch of its CVInsight medical device, according to a company statement. The device received 510(k) clearance from the U.S. Food and Drug Administration last year. The company sees initial applications for . The Pittsburgh Business Journal reported that it plans to add up to six sales and clinical testing staff in the near term. Amoruso said it would add up to 12 additional staff in the next 12-18 months.
